Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 12/28/15 → 10/26/18 |
Funding
- Eli Lilly and Company: $7,229.00
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After...
- Wu, Shenhong (PI)
- Keresztes, Roger (CoPI)
- Kudelka, Andrzej (CoPI)
Project: Research